Rheumatology Advance Access published online on May 16, 2006
Rheumatology, doi:10.1093/rheumatology/kel149
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 ARC Epidemiology Unit, University of Manchester, Manchester, UK
* To whom correspondence should be addressed. Background. Anti-tumour necrosis factor- Objective. To identify the clinical factors present at the start of anti-TNF- Methods. The British Society for Rheumatology (BSR) Biologics Register collects detailed data on all patients with a rheumatic disease receiving biologic therapy in the UK. We studied all patients with RA who had started etanercept (ETA) or infliximab (INF) and had achieved a minimum 6 months follow-up by 1 October, 2004. The disease status at the baseline and at 6 months was assessed using the Disease Activity Score (DAS28). The response was classified according to the European League against Rheumatism (EULAR) improvement criteria. The effect of baseline characteristics on response was studied using multivariate ordinal logistic regression. Results. 2879 patients were included in this analysis (1267 ETA, 1612 INF). At the start of therapy, the mean age was 55 yrs, disease duration 14 yrs, baseline DAS28 6.7 and health assessment questionnaire (HAQ) 2.1. In all, 28% of ETA and 86% of INF patients were receiving methotrexate. After 6 months, 18% had a good EULAR response, of whom 9% were considered to be in remission and 50% had a moderate response. There was no overall difference in response rate between the two anti-TNF- Conclusions. These data support an improved outcome among patients receiving MTX in combination with anti-TNF-
Received September 26, 2005
Accepted January 30, 2006
Original Papers
Predictors of response to anti-TNF-
Kimme L. Hyrich 1,
Kath D. Watson 1,
Alan J. Silman 1,
Deborah P. M. Symmons 1 *,
and
The BSR Biologics Register
therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
Deborah P. M. Symmons, E-mail: deborah.symmons{at}manchester.ac.uk
Abstract 
(TNF-) therapies represent an important advancement in therapy for rheumatoid arthritis (RA). However, there remains a proportion of patients who do not improve despite therapy. These drugs are expensive and have the potential of serious toxicity. Therefore, it would be ideal to predict the patients who will respond, so that the use of these drugs can be targetted. therapy that are associated with response at 6 months in patients with RA. therapies. A higher baseline HAQ score correlated with a lower response rate while a better response was associated with the current use of NSAIDs and the use of methotrexate (MTX), although the latter only reached statistical significance with ETA [OR 1.82 (95% CI 1.38-2.40)]. There was a lower response rate among current smokers, particularly in patients receiving INF [OR 0.77 (95% CI 0.60-0.99)]. Age, disease duration, rheumatoid factor and the previous number of disease-modifying antirheumatic drugs (DMARDs) did not predict response to either drug. However, females were less likely to achieve remission. therapies. However, the most disabled patients were less likely to respond, despite concurrent MTX. The benefits of NSAIDs may reflect the relative absence of comorbidities in patients who can tolerate these drugs or the continuing presence of reversible inflammatory symptoms. The association of smoking and poor outcome with INF is a novel finding and may reflect alterations in pharmacokinetics. The inability of other baseline disease characteristics to predict the outcome suggests that other factors, including potential genetic differences in drug metabolism, may be influencing the response to anti-TNF- therapies.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. D. Koller, D. Aletaha, J. Funovits, A. Pangan, D. Baker, and J. S. Smolen Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients Rheumatology, December 1, 2009; 48(12): 1575 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Hyrich, C. Deighton, K. D. Watson, BSRBR Control Centre Consortium, D. P. M. Symmons, M. Lunt, and on behalf of the British Society for Rheumatology Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity Rheumatology, October 1, 2009; 48(10): 1323 - 1327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. BARRA, J. E. POPE, and M. PAYNE Real-World Anti-Tumor Necrosis Factor Treatment in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: Cost-Effectiveness Based on Number Needed to Treat to Improve Health Assessment Questionnaire J Rheumatol, July 1, 2009; 36(7): 1421 - 1428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. SODERLIN, L. T.H. JACOBSSON, I. F. PETERSSON, M. ENGLUND, T. SAXNE, and P. GEBOREK Differences in Longitudinal Disease and Treatment Characteristics of Patients with Rheumatoid Arthritis Replying and Not Replying to a Postal Questionnaire. Experience from a Biologics Register in Southern Sweden J Rheumatol, June 1, 2009; 36(6): 1166 - 1169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. MATTEY, A. BROWNFIELD, and P. T. DAWES Relationship Between Pack-year History of Smoking and Response to Tumor Necrosis Factor Antagonists in Patients with Rheumatoid Arthritis J Rheumatol, June 1, 2009; 36(6): 1180 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E H Halvorsen, E A Haavardsholm, S Pollmann, A Boonen, D van der Heijde, T K Kvien, and O Molberg Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-{alpha} blocking agents Ann Rheum Dis, February 1, 2009; 68(2): 249 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Karonitsch, D Aletaha, M Boers, S Bombardieri, B Combe, M Dougados, P Emery, D Felson, J Gomez-Reino, E Keystone, et al. Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis Ann Rheum Dis, October 1, 2008; 67(10): 1365 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Hyrich, K. D. Watson, D. A. Isenberg, D. P. M. Symmons, and on behalf of the BSR Biologics Register The British Society for Rheumatology Biologics Register: 6 years on Rheumatology, October 1, 2008; 47(10): 1441 - 1443. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Pocock, J. C. Vasconcelos, and A. J. K. Ostor Assessment of anti-TNF-{alpha} efficacy in rheumatoid arthritis: is 3 months sufficient? Rheumatology, July 1, 2008; 47(7): 1073 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sekiguchi, S. Kawauchi, T. Furuya, N. Inaba, K. Matsuda, S. Ando, M. Ogasawara, H. Aburatani, H. Kameda, K. Amano, et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-{alpha} monoclonal antibody, infliximab Rheumatology, June 1, 2008; 47(6): 780 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Karlsson, L. E. Kristensen, M. C. Kapetanovic, A. Gulfe, T. Saxne, and P. Geborek Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register Rheumatology, April 1, 2008; 47(4): 507 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Kristensen, M. C. Kapetanovic, A. Gulfe, M. Soderlin, T. Saxne, and P. Geborek Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register Rheumatology, April 1, 2008; 47(4): 495 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Greenwood, J. Rathi, A. J. Hakim, D. L. Scott, and D. V. Doyle Regression to the mean using the disease activity score in eligibility and response criteria for prescribing TNF-{alpha} inhibitors in adults with rheumatoid arthritis Rheumatology, July 1, 2007; 46(7): 1165 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bobbio-Pallavicini, R. Caporali, C. Alpini, S. Avalle, O. M Epis, C. Klersy, and C. Montecucco High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor {alpha} inhibitors in rheumatoid arthritis Ann Rheum Dis, March 1, 2007; 66(3): 302 - 307. [Abstract] [Full Text] [PDF]
|
|